Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: HIV/AIDS, Diabetes Mellitus, Type 2, Hypertension
Interventions: Medication optimization intervention; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Gynecologic Cancer
Interventions: PSMA-based 18F-DCFPyL PET tracer; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Primary Aldosteronism, Hypertension
Interventions: Eplerenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: Buena Park, California • Huntington Park, California • Westlake Village, California + 10 more

Conditions: Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency, Hyperparathyroidism
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Rauscher, Gregory E., M.D. PA; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Diabetes, Gestational Diabetes
Interventions: human insulin, insulin NPH, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Adenocarcinoma, Pancreatic Neoplasms
Interventions: X-82, Everolimus; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: St Louis, Missouri • Nashville, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Hypertension, Diabetes Mellitus
Interventions: Self-monitoring-nurse-primary care provider feedback loop; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Medication Adherence
Interventions: Increasing Medication Adherence through Physician Incentives and Messaging; Other
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Type 2 Diabetes
Interventions: Coronary Health Improvement Project Program; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Riverside, California

Conditions: Gestational Diabetes
Interventions: continuous glucose monitor; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Conditions: Retinal Vasculitis
Interventions: aflibercept 2 mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Shift Work Type Circadian Rhythm Sleep Disorder, Diabetes Mellitus, Type 2, Circadian Rhythm Sleep Disorder, Shift Work Type, Insulin Resistance
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Nausea and Vomiting, Pancreatic Cancer, Primary Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: palonosetron hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 69
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions: atorvastatin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 1
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 36
States / cities: Fullerton, California • Long Beach, California • Sacramento, California + 31 more

Conditions: Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions: Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin; Drug
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more

Conditions: Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
Interventions: CI-1040; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 30
States / cities: Birmingham, Alabama • Blendora, California • Glendale, California + 23 more

Conditions: Cancer
Interventions: GSK1120212 plus everolimus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Search by objective public record fields.

Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)

PSMA PET and MRI in Gynecological Cancers

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

A Study for Participants With Type 2 Diabetes Mellitus

Vascular Risk After Kidney Transplantation

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Increasing Medication Adherence Through Physician Incentives and Messaging

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Intensive Lifestyle Intervention for Type 2 Diabetics: The KP TLC Pilot

Pregnancy and Postpartum CGM in GDM

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Shift Work, Heredity, Insulin, and Food Timing Study

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

High-dose Periop Statins for Prevention of DVT

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects